Isabel Morgado

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Gemini Consulting Group, Inc. provides management consulting services. Its services range from management consulting, to the development of day surgery centers and hospitals. The company was founded by James B. McCarthy and is headquartered in Oak Brook, IL.

BIAL-Portela & Cia SA manufactures pharmaceutical products. It develops drugs in therapeutic areas such as antibiotics, anti-inflammatory, anti-ulcer, anti-depressants, anti-asthmatic, and analgesics. The firm also offers anti-allergic vaccines and the means of diagnosing allergies. It has two production plants and two R&D centers in the Porto area and in Bilbao, Spain. The company was founded by António Portela in 1924 and is headquartered in Coronado, Portugal.

Associação Portuguesa de Gestão e Engenharia Industrial provides engineering and management services. The company was founded in 1985 and is headquartered in Porto, Portugal.

Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA.

ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier.